Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Boehringer Ingelheim
McKesson
Medtronic
Moodys
McKinsey

Last Updated: April 4, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for TAK-228


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

What is the drug development status for TAK-228?

TAK-228 is an investigational drug.

There have been 329 clinical trials for TAK-228. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2016.

The most common disease conditions in clinical trials are Diabetes Mellitus, Hypertension, and Diabetes Mellitus, Type 2. The leading clinical trial sponsors are Takeda, Millennium Pharmaceuticals, Inc., and National Cancer Institute (NCI).

There are twenty-nine US patents protecting this investigational drug and two hundred and sixty-two international patents.

Recent Clinical Trials for TAK-228
TitleSponsorPhase
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)National Cancer Institute (NCI)Phase 2
Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial)Southwest Oncology GroupPhase 2
Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Participants With Persistent/Chronic Primary Immune ThrombocytopeniaMillennium Pharmaceuticals, Inc.Phase 2

See all TAK-228 clinical trials

Clinical Trial Summary for TAK-228

Top disease conditions for TAK-228
Top clinical trial sponsors for TAK-228

See all TAK-228 clinical trials

US Patents for TAK-228

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
TAK-228   Start Trial Low, immune enhancing, dose mtor inhibitors and uses thereof Novartis AG (Basel, CH)   Start Trial
TAK-228   Start Trial Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases ZHEJIANG DTRM BIOPHARMA CO. LTD. (Hangzhou, CN)   Start Trial
TAK-228   Start Trial Combination pharmaceutical compositions and uses thereof INTELLIKINE LLC (La Jolla, CA)   Start Trial
TAK-228   Start Trial Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
TAK-228   Start Trial CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell Novartis AG (Basel, CH) The Trustees of the University of Pennsylvania (Philadelphia, PA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for TAK-228

Drugname Country Document Number Estimated Expiration Related US Patent
TAK-228 Australia 2014348657 2033-11-13   Start Trial
TAK-228 Australia 2017245411 2033-11-13   Start Trial
TAK-228 Canada 2929181 2033-11-13   Start Trial
TAK-228 China 105899232 2033-11-13   Start Trial
TAK-228 Eurasian Patent Organization 201690987 2033-11-13   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Express Scripts
Colorcon
Medtronic
McKesson
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.